Vasaprostane, lyophilizate 20 mcg 48.2 mg 10 pcs

Vasaprostane is a vasodilator, antiaggregative.

Vasaprostane is a drug of prostaglandin E1. It improves microcirculation and peripheral circulation.

Limits arterioles and postcapillary sphincters tone, decreases PPS with no change in BP, increases coronary blood flow and left ventricular ejection fraction.

It improves rheological properties of blood by reducing platelet adhesion and aggregation, reducing aggregation and improving erythrocyte deformability, increasing fibrinolytic activity and reducing blood viscosity.

It affects the metabolism, increases glucose and oxygen utilization, inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates protein synthesis, has a beneficial effect on lipid metabolism (inhibition of cholesterol synthesis and reduction of LDL concentration), inhibits proliferation and mitosis of smooth muscle cells.

With Vasaprostan treatment the severity of pain at rest decreases, the healing of trophic ulcers accelerates, remission of the disease occurs.

Indications

Treatment of chronic obliterating diseases of the arteries of stages III and IV.

Pharmacological effect

Vasodilator, antiaggregant.

Vazaprostan is a prostaglandin E1 drug. Improves microcirculation and peripheral circulation.

Reduces the tone of arterioles and post-capillary sphincters, reduces peripheral vascular resistance without changing blood pressure, increases coronary blood flow and left ventricular ejection fraction.

Improves the rheological properties of blood by reducing platelet adhesion and aggregation, reducing aggregation and improving the deformability of erythrocytes, increasing fibrinolytic activity and reducing blood viscosity.

It affects metabolism, increases the utilization of glucose and oxygen, inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates protein synthesis, has a beneficial effect on lipid metabolism (suppression of cholesterol synthesis and reduction of LDL concentration), inhibits the proliferation and mitosis of smooth muscle cells.

During treatment with Vazaprostan, the severity of pain at rest decreases, the healing of trophic ulcers accelerates, and remission occurs during the course of the disease.

Special instructions

During treatment with Vazaprostan, patients with signs of renal and heart failure should limit the volume of fluid to 50-100 ml/day.

During therapy, blood pressure and heart rate should be monitored, and if necessary, fluid balance should be monitored, central venous pressure should be measured, and echocardiography should be performed. The clinical effectiveness of treatment is assessed after 3 weeks of therapy.

During therapy with Vazaprostan, the appearance of C-reactive protein may be observed in a biochemical blood test.

Active ingredient

Alprostadil

Composition

1 ampoule contains alprostadil (in the form of alpha-cyclodextrin) 20 mcg;

excipients:

lactose;

alphadex.

Contraindications

– chronic heart failure in the stage of decompensation;
– acute myocardial infarction and post-infarction period for 6 months;
– severe heart rhythm disturbances;
– acute circulatory failure (shock, vascular collapse);
– severe arterial hypotension (systolic blood pressure less than 90 mm Hg);
– severe liver dysfunction;
– peptic ulcer of the stomach and duodenum;
– hypersensitivity to the drug.

Side Effects

From the cardiovascular system: palpitations, arterial hypotension, headache; in isolated cases – increased frequency of angina attacks, development of pulmonary edema, and symptoms of heart failure.

From the digestive system: dyspeptic symptoms, increased activity of liver transaminases.

Other: leukopenia, leukocytosis; with long-term therapy (more than 4 weeks) in isolated cases, hyperostosis of tubular bones.

Local reactions: swelling, hyperemia, pain at the injection site.

Interaction

With simultaneous use, Vazaprostan may enhance the hypotensive effect of antihypertensive drugs, peripheral vasodilators, and antianginal drugs.

When Vazaprostan is used in combination with anticoagulants and antiplatelet agents, the likelihood of developing hemorrhagic syndrome increases.

Overdose

Symptoms: decreased blood pressure, skin hyperemia, weakness.

Treatment: drug infusion should be slowed down or stopped; If necessary, carry out symptomatic therapy.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

IDT Biology GmbH, Germany